CYP19A1 and benign prostatic hyperplasia: The ability of β-sitosterol and other phytosterols to inhibit aromatase and 5-alpha-reductase has been well documented, and this inhibitory capacity has been exploited to treat pathologies such as benign prostatic hyperplasia and androgenetic alopecia [26,27,28].